On January 29, Shenzhen Tisenc Medical Devices Co., Ltd. underwent an industrial and commercial change. All the original shareholders withdrew, and WONDFO BIOTECH (300482) was newly added, holding 100% of the shares.

TISENC Medical is a developer of in vitro reagents and POCT projects. The company was established in 2015. Its business scope includes: clinical inspection and analysis instruments and reagents, daily chemicals, and chemicals (excluding hazardous chemicals) Purchase and sale, import and export business etc.

WONDFO BIOTECH has been committed to the POCTization of large-scale chemiluminescence instruments for many years. Since 2021, WONDFO BIOTECH's miniaturized chemiluminescence products have taken the "six items of thrombus" detection products as the sharp knife project, and have quickly opened up the market of some tertiary hospitals and secondary hospitals in China with its excellent performance.

About Wondfo (CACLP Booth NO. A4-0501)

Guangzhou Wondfo Biotech Co., Ltd., headquartered in Guangzhou science city, has been focusing on the R&D, production, sales and service of point-of-care testing (POCT) products and providing customers with professional rapid diagnosis and chronic disease management solutions since founded in 1992.
Wondfo now has more than 3000 employees and a wide range of products for the rapid identification of cardiovascular diseases, inflammation, tumor, infectious diseases, drug abuse, pregnancy, and so on, widely sold to 140+ countries and regions.